N-methyl-3,3-dimethylpyrrolidine-2,5-dione | 1628-18-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-methyl-3,3-dimethylpyrrolidine-2,5-dione
• 英文别名: 1,3,3-trimethylpyrrolidine-2,5-dione；1,3,3-trimethyl-pyrrolidine-2,5-dione；1,3,3-Trimethyl-pyrrolidin-2,5-dion；1,3,3-Trimethyl-succinimid
• CAS: 1628-18-8
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: QXWKTXZMMDGVMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-3,3-dimethylpyrrolidine-2,5-dione 生成 N-methyl-3-methyl-2-butenamide
  参考文献：
  名称：

  Photoinduced reactions. 39. Photochemistry of the imide system. 9. Norrish type I reaction of aliphatic cyclic imides. General reaction pattern, competition with type II processes, and some synthetic application

  摘要：

  DOI：

  10.1021/jo01324a050
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 sodium ethanolate 作用下， 生成 N-methyl-3,3-dimethylpyrrolidine-2,5-dione
  参考文献：
  名称：

  alpha,alpha-n-trimethyl succinimide

  摘要：

  公开号：

  US02614106A1

文献信息

• SPIRO COMPOUND AND USE THEREOF
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20200048235A1

  公开（公告）日：2020-02-13

  The present disclosure relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine-1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acceptable salts thereof.

  本公开涉及一系列三环化合物及其作为鞘氨醇-1-磷酸酯亚型1（S1P1）受体激动剂的用途，特别涉及如化学式（I）所示的化合物或其药用可接受的盐。
• Intermolecular Photocycloaddition of Ring-Substituted Cyclic Dithioimides with 2,3-Dimethyl-2-butene: A Facile Synthesis of Spiro-Thietanes
  作者：Kazuaki Oda、Minoru Machida、Yuichi Kanaoka

  DOI：10.1055/s-1986-31772

  日期：——

  Upon irradiation, unsymmetrically 3-substituted and symmetrical bicyclic dithiosuccinimides undergo photocycloaddition with 2,3-dimethyl-2-butene to give various spiro-thietanes, including highly strained multicycles.

  在辐照下，不对称的3取代和对称的双环二硫琥珀酰亚胺与2,3-二甲基-2-丁烯发生光环加成反应，生成各种螺环噻烯，包括高度受压的多环化合物。
• Synthesis of Chiral γ-Lactams via in Situ Elimination/Iridium-Catalyzed Asymmetric Hydrogenation of Racemic γ-Hydroxy γ-Lactams
  作者：Qianjia Yuan、Delong Liu、Wanbin Zhang

  DOI：10.1021/acs.orglett.7b00651

  日期：2017.4.7

  Chiral γ-lactams have been synthesized in excellent yields and enantioselectivities (up to 99% yield and 96% ee) from easily accessible racemic γ-hydroxy γ-lactams via an iridium-phosphoramidite catalyzed asymmetric hydrogenation. The reaction was designed based on insight into the reaction mechanism demonstrated in previous work and can be carried out at a reduced catalyst loading of 0.1 mol % on

  通过铱-亚磷酰胺催化的不对称加氢反应，由易于获得的外消旋γ-羟基γ-内酰胺以极高的收率和对映选择性（高达99％收率和96％ee）合成了手性γ-内酰胺。该反应是基于对先前工作中证明的反应机理的了解而设计的，并且可以在克量的0.1mol％的降低的催化剂负载量下进行。可以从还原产物中合成几种潜在的生物活性化合物。机理研究表明，还原产物是通过氢化由γ-羟基γ-内酰胺生成的N-酰基亚胺阳离子获得的。
• CYCLIC PEPTIDES AND USE AS MEDICINES
  申请人：Fu Jiping

  公开号：US20140134132A1

  公开（公告）日：2014-05-15

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R 1 , R 2 , R 3 , R 4 , R 5 , and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.

  本发明提供了一种化合物I的公式；或其药学上可接受的盐，其中变量R1、R2、R3、R4、R5和A-B在此处定义，这些化合物是非免疫抑制剂、环肽酶结合剂、mPTP阻滞剂，因此可用于预防或治疗HCV感染、中风、多发性硬化、HBV感染、HPV感染、哮喘、癌症、肌萎缩症、败血症、缺血/再灌注损伤和心力衰竭等疾病或紊乱。
• DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Hatayama Akira

  公开号：US20100087442A1

  公开（公告）日：2010-04-08

  The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).

  本发明涉及式(I)的二酮肼衍生物及其药学上可接受的盐（式中符号与说明书中描述的含义相同）。式(I)化合物具有对半胱氨酸蛋白酶的抑制活性，可用于治疗炎症性疾病、免疫性疾病、缺血性疾病、呼吸系统疾病、循环系统疾病、血液疾病、神经系统疾病、肝胆系统疾病、骨骼或关节疾病、代谢性疾病等。该化合物具有对弹性蛋白酶的抑制活性，也可用于治疗慢性阻塞性肺部疾病（COPD）。